Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun 13;14(3):R93.
doi: 10.1186/bcr3208.

Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach

Tim J A Dekker  1 , Susan Ter Borg, Gerrit K J Hooijer, Sybren L Meijer, Jelle Wesseling, James E Boers, Ed Schuuring, Jos Bart, Joost van Gorp, Wilma E Mesker, Judith R Kroep, Vincent T H B M Smit, Marc J van de Vijver
Affiliations

Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach

Tim J A Dekker et al. Breast Cancer Res. .

Abstract

Introduction: Overexpression of the human epidermal growth factor receptor 2 (HER2) as a result of HER2 gene amplification is associated with a relatively poor prognosis in breast cancer and is predictive of HER2-targeting therapy response. False-positive rates of up to 20% for HER2 testing have been described. HER2-testing laboratories are therefore encouraged to participate in external quality control schemes in order to improve HER2-testing standardization.

Methods: This study investigated the feasibility of retesting large numbers of invasive breast cancers for HER2 status on tissue micro-array (TMA) as part of a quality control scheme. For this assessment different HER2 testing methods were used including HER2 detecting antibodies SP3, 4B5, Herceptest and mono color silver in situ hybridization (SISH) and dual color SISH. Final HER2 status for each tumor on the TMA was compared to the local testing result for the same tumor. Discordances between these two results were investigated further by staining whole tumor sections.

Results: For this study, 1,210 invasive breast carcinomas of patients treated in six hospitals between 2006 and 2008 were evaluated. Results from the three immunohistochemistry (IHC) and two in situ hybridization (ISH) assays performed on the TMAs were compared. The final HER2 status on TMA was determined with SP3, 4B5 and mono color SISH. Concordance between local HER2 test results and TMA retesting was 98.0%. Discordant results between local and TMA retesting were found in 20 tumors (2.0%). False positive HER2 IHC results were identified in 13 (1.3%) tumors; false negative IHC results in seven (0.7%) tumors.

Conclusions: Retesting large volumes of HER2 classified breast carcinomas was found to be feasible and can be reliably performed by staining TMAs with SP3, 4B5 and mono color SISH in combination with full-sized slides for discordant cases. The frequency of false-positive results was lower than previously reported in the literature. This method is now offered to other HER2-testing laboratories.

PubMed Disclaimer

Figures

Figure 1
Figure 1
TMA core displaying completely negative staining for HER2 (4B5 antibody). HER2, human epidermal growth factor receptor 2; TMA, tissue micro-array.
Figure 2
Figure 2
TMA core displaying weak membranous HER2 staining (2+, 4B5 antibody). HER2, human epidermal growth factor receptor 2; TMA, tissue micro-array.
Figure 3
Figure 3
TMA core displaying strong membranous HER2 staining (3+, 4B5 antibody). HER2, human epidermal growth factor receptor 2; TMA, tissue micro-array.
Figure 4
Figure 4
Tumor that displayed HER2 protein overexpression in the absence of gene amplification (mono color SISH negative). HER2, human epidermal growth factor receptor 2; SISH, silver in situ hybridization.
Figure 5
Figure 5
Tumor that displayed HER2 protein overexpression in the absence of gene amplification (3+, SP3 antibody). HER2, human epidermal growth factor receptor 2.
See this image and copyright information in PMC

References

    1. Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, Gralow JR, Livingston RB, Gown AM. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004;291:1972–1977. doi: 10.1001/jama.291.16.1972. - DOI - PubMed
    1. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004;5:63–69. doi: 10.3816/CBC.2004.n.011. - DOI - PubMed
    1. Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 1998;16:462–469. - PubMed
    1. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco AR, De Placido S. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol. 1996;14:2702–2708. - PubMed
    1. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, Liu ET. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998;90:1346–1360. doi: 10.1093/jnci/90.18.1346. - DOI - PubMed

Publication types

LinkOut - more resources